HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Festuccia, C. Articles by Bologna, M. Search for Related Content PubMed PubMed Citation Articles by Festuccia, C. Articles by Bologna, M.

¹ Departments of Experimental Medicine,
² Surgery, University of L’Aquila, 67100 L’Aquila, Italy
³ Pathology Departments of G Mazzini Hospital, 68100 Teramo, Italy
⁴ San Salvatore Hospital, 67100 L’Aquila, Italy
⁵ Department of Urology, University of Washington, Seattle, Washington 98195, USA
⁶ Department of Basic and Applied Biology, University of L’Aquila, 67100 L’Aquila, Italy

(Correspondence should be addressed to C Festuccia, Dipartimento di Medicina Sperimentale, Cattedra di Patologia Generale, Università dell’Aquila, Via Vetoio, Coppito 2, 67100 L’Aquila, Italy; Email: festucci{at}univaq.it)

C Festuccia and G L Gravina contributed equally to this work

Bicalutamide monotherapy is emerging as an alternative in the treatment of locally advanced prostate cancer. However, a significant number of these patients will recur and be in need of second-line therapies. The knowledge of molecular arrangements after pharmacological therapy seems to be a new primary prerequisite to predict the efficacy or the failure of a secondary therapy. Based on these considerations, we have conducted this study in order to analyze the expressions of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Akt, epidermal growth factor receptor (EGFR), phospho-EGFR (p-EGFR), human EGFR2 (Her2), and phospho-Her2 (p-Her2) after bicalutamide treatment. For this purpose, we evaluated retrospectively 69 prostate cancer tissues derived from patients who received radical prostatectomy as the only treatment, and 81 from patients who received bicalutamide for 120 days before surgery. In addition, we analyzed at different time points the effects of castration performed on athymic mice bearing the LuCaP 35 xenograft line at different times. We observed that bicalutamide treatment increased significantly the levels of p-Akt, EGFR, and Her2 with a concomitant reduction in PTEN. This effect was time dependent and required of sufficient time to be evident as indicated by data obtained with the LuCaP 35 tumors. A logistic multiple regression analysis revealed that a switch of p-Akt control from a PTEN/EGFR- to Her2-after bicalutamide treatment was possible. Since Akt and Her2 can be associated with reduced drug sensitivity, our report suggests that the evaluation of molecular arrangements after bicalutamide treatment could be useful to identify subsets of patients who will be molecular permissive for new adjuvant anti-target therapies.

This article has been cited by other articles:

				M. R. Epis, K. M. Giles, A. Barker, T. S. Kendrick, and P. J. Leedman miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer J. Biol. Chem., September 11, 2009; 284(37): 24696 - 24704. [Abstract] [Full Text] [PDF]